4-[5-(4-Fluoro-phenyl)-3-piperidin-4-yl-3H-imidazol-4-yl]-2-(2-methoxy-phenoxy)-pyrimidine

ID: ALA417804

Chembl Id: CHEMBL417804

PubChem CID: 15872406

Max Phase: Preclinical

Molecular Formula: C25H24FN5O2

Molecular Weight: 445.50

Molecule Type: Small molecule

Names and Identifiers

Synonyms: SB-251527 | SB-251527 | SB-251527|CHEMBL417804|4-[4-(4-Fluorophenyl)-1-(Piperidin-4-Yl)-1h-Imidazol-5-Yl]-2-(2-Methoxyphenoxy)pyrimidine|4-(4-(4-Fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl)-2-(2-methoxyphenoxy)pyrimidine|SCHEMBL4915397|HMS3303D22|HMS3305F07|BDBM50099334|NSC756431|NSC-756431|NCGC00242190-01|AB01092365-01|Q27453215|2RQ|4-[5-(4-Fluoro-phenyl)-3-piperidin-4-yl-3H-imidazol-4-yl]-2-(2-methoxy-phenoxy)-pyrimidine

Canonical SMILES:  COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1

Standard InChI:  InChI=1S/C25H24FN5O2/c1-32-21-4-2-3-5-22(21)33-25-28-15-12-20(30-25)24-23(17-6-8-18(26)9-7-17)29-16-31(24)19-10-13-27-14-11-19/h2-9,12,15-16,19,27H,10-11,13-14H2,1H3

Standard InChI Key:  RGWJYCCSHANDCO-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA417804

   4-[4-(4-Fluorophenyl)-1-(Piperidin-4-Yl)-1h-Imidazol-5-Yl]-2-(2-Methoxyphenoxy)pyrimidine

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 445.50

Molecular Weight (Monoisotopic): 445.1914

AlogP: 4.87

#Rotatable Bonds: 6

Polar Surface Area: 74.09

Molecular Species: BASE

HBA: 7

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 7

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 10.13

CX LogP: 3.95

CX LogD: 1.34

Aromatic Rings: 4

Heavy Atoms: 33

QED Weighted: 0.46

Np Likeness Score: -0.91

References

1. Boehm JC, Bower MJ, Gallagher TF, Kassis S, Johnson SR, Adams JL..  (2001)  Phenoxypyrimidine inhibitors of p38alpha kinase: synthesis and statistical evaluation of the p38 inhibitory potencies of a series of 1-(piperidin-4-yl)-4-(4-fluorophenyl)-5-(2-phenoxypyrimidin-4-yl) imidazoles.,  11  (9): [PMID:11354358] [10.1016/s0960-894x(01)00163-9]

2. Ravindra GK, Achaiah G, Sastry GN..  (2008)  Molecular modeling studies of phenoxypyrimidinyl imidazoles as p38 kinase inhibitors using QSAR and docking.,  43  (4): [PMID:17706839] [10.1016/j.ejmech.2007.06.009]

3. PubChem BioAssay data set, 

4. Compounds: GSK PKIS; Assays: Nanosyn kinase panel,  [10.6019/CHEMBL1961873]

5. Compounds: GSK PKIS; Assays: UNC Frye lab,  [10.6019/CHEMBL2007661]

6. Data associated with the publication PLoS ONE, 8(3), e57888, (2013) PMID: 23505445. Compounds: GSK PKIS; Assays: NIH NCATS, 

7. Carlino L, Rastelli G..  (2016)  Dual Kinase-Bromodomain Inhibitors in Anticancer Drug Discovery: A Structural and Pharmacological Perspective.,  59  (20): [PMID:27559828] [10.1021/acs.jmedchem.6b00438]

Source

Source(3):

• Scientific Literature
• PubChem BioAssays
• GSK Published Kinase Inhibitor Set